title: Costs of congenital rubella syndrome (CRS) in Oman: evidence based on long-term follow-up of 43 children.
abstract: As part of the national plan for elimination of rubella and congenital rubella syndrome (CRS), Oman established a national registry of CRS cases. As of May 2005, the registry included 43 surviving CRS cases, with a mean age of 11.9 years. Clinical examinations found that 84% had ocular defects, 84% had auditory/speech defects, 70% had neurological manifestations, and 42% had cardiac defects. Lifetime medical, special education, and rehabilitation costs were assessed. Using a discount rate of 3%, the average direct lifetime cost per surviving CRS patient was estimated at 18,644 US dollars. When including predicted lost productivity due to CRS, the average discounted direct and indirect lifetime costs per surviving CRS patient amounted to 98,734 US dollars.
authors.affiliation: Department of Communicable Disease Surveillance and Control, Directorate General of Health Affairs, Ministry of Health, Muscat, Sultanate of Oman. awadymoh@omantel.net.om
authors.forename: Salah
authors.initials: S
authors.lastname: Al-Awaidy
authors.forename: Ulla K
authors.initials: UK
authors.lastname: Griffiths
authors.forename: Hosammudin Mohammed
authors.initials: HM
authors.lastname: Nwar
authors.forename: Shyam
authors.initials: S
authors.lastname: Bawikar
authors.forename: Masoud Salim
authors.initials: MS
authors.lastname: Al-Aisiri
authors.forename: Rajiv
authors.initials: R
authors.lastname: Khandekar
authors.forename: Ali Jaffer
authors.initials: AJ
authors.lastname: Mohammad
authors.forename: Susan E
authors.initials: SE
authors.lastname: Robertson
mesh_terms: D002648:Child; D003365:Costs and Cost Analysis; D005128:Eye Diseases / Q000151:congenital / Q000191:economics / Q000628:therapy; D005500:Follow-Up Studies; D006311:Hearing Disorders / Q000151:congenital / Q000191:economics / Q000628:therapy; D006330:Heart Defects, Congenital / Q000191:economics / Q000628:therapy; D006801:Humans; D007231:Infant, Newborn; D009422:Nervous System Diseases / Q000151:congenital / Q000191:economics / Q000628:therapy; D009850:Oman; D012410:Rubella Syndrome, Congenital / Q000188:drug therapy / Q000191:economics* / Q000534:rehabilitation / Q000628:therapy*; D012412:Rubella virus; D013064:Speech Disorders / Q000191:economics / Q000628:therapy; D013997:Time Factors